To date, and according to the literature reviewed in this manuscript, Panx1 inhibitors and modulators have demonstrated considerable therapeutic potential in numerous preclinical models of inflammatory, autoimmune, cardiovascular, and neurodegenerative diseases. This evidence concerns the gene PANX1 and neurodegenerative disease.